Recent advancements in drug delivery technologies utilizing a variety of carriers have
resulted in a path-breaking revolution in the approach towards diagnosis and therapy alike …

Pancreatic cancer (PC) is a fatal disease that has a poor 5-year survival rate. The poor
prognosis can be attributed to both troublesome detections at the initial stage, which makes …

Synergistic therapy that combines chemo‐, gene‐, or photothermal means shows great
potential for enhancing the therapeutic effects on cancers. Tumor‐targeted nanoparticles …

Curcumin-loaded mesoporous silica nanoparticles (MSNs) have shown promise as drug
delivery systems to address the limited pharmacokinetic characteristics of curcumin …

Nanoparticle drug formulations have been extensively investigated, developed, and in some
cases, approved by the Food and Drug Administration (FDA). Synergistic combinations of …

Poorly water-soluble drugs demonstrate significant challenge in pharmaceutical
development, which is linked to their limited oral bioavailability and therapeutic efficacy. To …

Mesoporous silica nanoparticles have attracted much attention in recent years as drug and
gene delivery systems for biomedical applications. Among their most beneficial features for …

Co-delivery of anticancer drugs and biologics can provide synergetic effects and outperform
single delivery therapies. Here, a nanoparticle (NP) system for co-delivery of methotrexate …

Pancreatic cancer (PC) is one of the leading causes of death and is the fourth most
malignant tumor in men. The epigenetic and genetic alterations appear to be responsible for …

Despite numerous advantages, curcumin's (CUR) low solubility and low bioavailability limit
its employment as a free drug. CUR‐incorporated nanoformulation enhances the …